

Diabetes (DM)

Type I

Diagnosis/Condition:	Insulin Dependent Diabetes mellitus Type I Diabetes mellitus
Discipline:	ND
ICD-10 Codes:	E08.9; E09.9; E13.9; E11.9
Origination Date:	2012
Review/Revised Date:	10/2023
Next Review Date:	10/2025

Type I Diabetes mellitus (T1D) is a chronic autoimmune disease in which blood sugar (glucose) levels are abnormally high caused by insulin deficiency following the destruction of immune-mediated insulin-producing pancreatic β cells, which is attributed to genetic and environmental factors.¹ It was formerly referred to as insulin dependent diabetes mellitus (IDDM) or juvenile diabetes, as it is often diagnosed in childhood. 14% of new cases are in adults, and usually develop before age 30. In the United States, the overall incidence of T1D seems to be rising in most age and ethnic groups.^{2,3} According to the data from the International Diabetes Federation Atlas 2021, approximately 1.2 million children and adolescents are diagnosed with T1DM in 2021.⁴ Approximately twenty six percent (26%) of U.S. adults with diabetes reported using some form of CAM in 2017.^{5,6}

In T1D, more than 90% of the insulin-producing (Beta) cells of the pancreas are permanently destroyed producing little or no insulin. About 10% of all people with diabetes have Type I disease. The new diagnosis of T1D can be very challenging for both children and adults. Ongoing education and management is critical.

OTHER TYPES OF DIABETES

Metabolic syndrome (syndrome X or insulin-resistance syndrome): thought to be due to developing insulin resistance and can occur in patients with overtly normal glucose tolerance, prediabetes, or diabetes. Diagnosed when a patient has at least 3 of the following 5 conditions:

1. Abdominal obesity.
2. Elevated triglyceride level.
3. Low level of high-density lipoprotein (HDL) cholesterol.
4. Elevated blood pressure (BP).
5. Fasting glucose value of 100 mg/dL or higher.

Pre-diabetes: glucose levels are too high to be considered normal but not high enough to be labeled diabetes. Fasting glucose levels - between 101 mg/dL and 126 mg/dL or glucose level 2 hours after a glucose tolerance test between 140 mg/dL and 200 mg/dL. Decreasing body weight by 5 to 10% through diet and exercise can significantly reduce the risk of developing future diabetes.

Gestational Diabetes Mellitus (GDM): diabetes diagnosed during pregnancy.

Type II (T2D): (formerly called non-insulin-dependent diabetes mellitus or adult-onset diabetes) - the pancreas continues to produce insulin, sometimes even at higher-than-normal levels. However, the body develops resistance to the effects of insulin so there is not enough insulin to meet the body's needs. Usually begins in people older than 30 and becomes progressively more common with age. About 15% of people older than 70 have T2D. Can be a genetic predisposition. Obesity is a chief risk factor for developing T2D. Eighty to ninety percent of people with T2D are overweight or obese.

Successful management includes:

- Balancing strict glycemic control.
- Setting realistic goals for each patient and family, while considering the patient's age and developmental status. The level of family involvement is key in establishing a practical management plan that can be implemented.
- Maintaining normal growth, development, and emotional maturation in childhood.
- Increasing independence and self-care as the diabetic child grows is an ongoing goal.
- Educating the patient and family in daily diabetes care (including insulin administration and blood glucose testing) in order to attain glucose control within the range of predetermined goals, and to recognize and treat hypoglycemia.

Potential Risk Factors

- Can be an environmental, viral, nutritional, genetic predisposition.
- T1D risk factors may include the following:^{7,6}
 - Genetic causes: HLA genes on chromosome 6 (1 in 10 with this gene develop T1D).
 - Family members with T1D.⁸
 - Viral infections: particularly enterovirus infections, rubella, coxsackievirus, mump.
 - Higher risk race/ethnicity: Caucasians have slightly higher incidence of T1D.
 - Diet, especially exposure to cow's milk at an early age.⁹
 - Higher socioeconomic status.
 - High birth weight.
 - Family increased incidence of autoimmune disease, including Graves, MS, pernicious anemia.
 - Living in northern climates.
 - Abdominal injury resulting in pancreatic damage.

Subjective Findings and History

- Can be asymptomatic.
- Classic presentation: new onset of chronic polydipsia, polyuria, and weight loss with hyperglycemia and ketonemia (or ketonuria).
- Increased appetite without weight gain.

- Polycystic ovarian syndrome (PCOS).
- Diabetic ketoacidosis (fruity breath).
- Family history of diabetes.
- Blurry vision or other visual disturbances.
- Hunger, weight loss
- Fatigue, irritability.
- Neuropathies/paresthesias.
- Yeast infections/balanitis.
- Abdominal pain.
- Erectile dysfunction.
- Menstrual disorders, spontaneous abortion.
- Headache.
- Dehydration.

Complications

Diabetes is a life-long disease. Sequelae of end-organ damage can develop over months to years. Morbidity from diabetes is a consequence of both macrovascular disease (atherosclerosis) and microvascular disease (retinopathy, nephropathy, and neuropathy). If blood glucose levels are not well-controlled, complications can include: arteriosclerosis, atherosclerosis, other cardio-vascular disease (CVD), strokes, claudication, vision problems (diabetic retinopathy), (poly) neuropathies, limb weakness, skin ulcers and infections (fungal and bacterial), renal failure, injuries and falls, and diabetic ketoacidosis. Acute hypoglycemia can occur and is a medical emergency.

Diagnosis and Differential Diagnosis

- Metabolic Syndrome.
- Pre-diabetes.
- T2D.
- Celiac disease.
- Gestational diabetes.
- Other causes of hyperglycemia.
- Secondary hyperglycemia can be caused by physiological stresses (such as acute infection and trauma) or by various endocrine conditions.

The American Diabetes Association (ADA) criteria for the diagnosis of T1D are any of the following signs of abnormal glucose metabolism:¹⁰

• An HbA1c level of 6.5% or higher*; or
• A fasting plasma glucose (FPG) level of 126 mg/dL (7.0 mmol/L) or higher; fasting is defined as no caloric intake for at least 8 hours, or
• A 2-hour plasma glucose level of 200 mg/dL (11.1 mmol/L) or higher during a 75-g oral glucose tolerance test (OGTT), or

- A random plasma glucose (RPG) of 200 mg/dL (11.1 mmol/L) or higher in a patient with classic symptoms of hyperglycemia (i.e., polyuria, polydipsia, polyphagia, weight loss) or hyperglycemic crisis

*The American Association of Clinical Endocrinologists recommends that HbA1c be considered an additional optional diagnostic criterion for long term trends, rather than a primary criterion for diagnosis of diabetes.¹¹

Objective Findings and Assessment

A workup should be done when a patient presents with symptoms or in asymptomatic patients who present with random serum glucose levels (>140 mg/dL).

Physical Exam (should be performed two to three times yearly), Testing, and Vaccinations¹² (these are very similar for T1D and T2D patients):

Management and Physical Exam	Frequency	Comments
Smoking cessation counseling	Every visit	For smokers only
Blood pressure	Every visit	Goal <130/80, or <140/90 ^{13,14,15,16,17} (guidelines vary)
Dilated eye examination (fundoscopic)	Annually	Begin at onset of T2DM, three to five years after onset of T1DM. Examine more than annually if significant retinopathy
Foot examination	Annually	Every visit if peripheral vascular disease or neuropathy is present (include inspection, assessment of foot pulses, reflexes, and testing for loss of protective sensations and vibration)
Skin examination	Every visit	For acanthosis nigricans and insulin injection sites
Thyroid evaluation/palpation	Annually	
Cardiovascular exam and studies		Stress test if indicated or if beginning exercise program
Dental screening	Annually	
Cancer screening	Variable	Some studies have suggested an increased risk of cancer in patients with diabetes, possibly related to the coincident obesity
Psychosocial-Mental Health screening	Variable	Referral as indicated – screen for depression, anxiety, eating disorders, cognitive impairment

Laboratory Studies	Frequency	Comments
Fasting serum lipid profile	Annually	May obtain every two years if profile is low risk.
Antibodies	Once	There is no specific test to distinguish between the two types of diabetes, T1DM is suggested by the presence of circulating, pancreatic autoantibodies. The absence of pancreatic autoantibodies does not rule out the possibility of T1D. Up to 30 percent of individuals with the classical appearance and presentation of T2D have positive autoantibodies and may have a slowly progressive type of autoimmune diabetes.
Blood glucose	Every visit	The patient should check multiple times per day
Insulin and C-peptide levels	Initial and consider annual	High fasting insulin and C-peptide levels suggest T2D. Levels are inappropriately low or in the normal range relative to the concomitant plasma glucose concentration in T1DM. At presentation, insulin and C-peptide levels may be suppressed by severe hyperglycemia and illness.
HA1C	Every three to six months	Goal 6-7 percent (may be lower or higher in selected patients)
Microalbuminuria – persistent values between 30 and 300 mg/day (20 to 200 mcg/min)	Annually	Begin three to five years after onset of type 1 diabetes; protein excretion and serum creatinine should also be monitored if persistent albuminuria is present
Liver function tests (LFTs) and thyroid panel	Annually	
Potassium, serum creatinine and glomerular filtration rate (GFR)	Annually	GFR should be followed closely and nephrology referral based upon National Kidney Foundation guidelines ¹⁸
Vaccinations	Frequency	Comments
Pneumococcus	One time	Patients over age 65 need a second dose if vaccine was received ≥5 years

		previously and age was <65 at time of vaccination
Influenza	Annually	
Hepatitis B	Three dose series	Administer to unvaccinated adults who are ages 19 to 59 years; For older patients, administer based upon risk of acquiring HBV and likelihood of adequate immune response to vaccination
Other	Frequency	Comments
Education, self-management review	Annually	
Carry or wear medical identification (bracelet or tag)	At all times	Alert of diagnosis in an emergency

Plan

A main goal of diabetes treatment is to keep blood sugar levels within the normal range to prevent hypoglycemia and resultant comorbidities. Treatment involves diet, exercise, education, and supplemental insulin. If people with diabetes strictly control blood sugar levels, complications are less likely to develop. People with T1D who are able to maintain a healthy weight may be able to reduce their doses of insulin. Many families with children with T1D use complementary and alternative medicine (CAM) as adjunctive treatment for controlling symptoms.^{6,7}

Lifestyle and dietary Modifications:

- Dietary modification (i.e. Low glycemic index diet, DASH diet, Bernstein diet).¹⁹
- Fish consumption, long chain fatty acids.²⁰
- Meals should be eaten on a regular schedule and long periods between eating should be avoided.
- Exercise to help people control their weight and maintain blood sugar levels within the normal range. Because blood sugar levels go down during exercise, patients must be alert for symptoms of low blood sugar.²¹
- Weight reduction/maintenance.²²
- Smoking cessation. A meta-analysis of many of the cardiovascular risk reduction trials showed that cessation of smoking had a much greater benefit on survival than most other interventions.²³
- Consume no more than moderate amounts of alcohol.
- Tight glycemic control (target A1C <6.5 percent with intensive therapy).
- Tight blood pressure control (target <140/85 mmHg for most of the study and <130/80 mmHg for the last two years).

Manual Adjustments/Manipulation:

- Chiropractic manipulation and treatment for musculoskeletal sequelae.²⁴

Supplements and Nutrients: (Note: this is for adult treatment; treatment in children may differ and be contraindicated)

- Vitamin C, vitamin D, folate, and chromium picolinate.²⁵
- American Ginseng (*Panax quinquefolium*).^{26,27,28}
- *Ocimum sanctum* (Holy basil).^{29,30}
- *Trigonella foenum-graecum* (Fenugreek).^{31,32}
- *Cinnamomum cassia* (Cinnamon).^{33,34}
- *Gymnema sylvestre* (Gurmar).^{35,36,37,38}
- Chromium (Polynicotinate).^{39,40}
- Biotin.⁴¹
- Vanadium Sulfate.
- Alpha lipoic acid (diabetic neuropathy).^{42,43,44}
- Magnesium.

Pharmaceuticals (Prescription): Insulin is necessary in T1D.

- Angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy should be considered in adults.
- In all patients ≤ 40 years old with diabetes, moderate intensity statin treatment should be considered; higher doses should be considered in those with increased CVD risk.¹⁰
- Aspirin. The merits of daily aspirin therapy in patients with macrovascular disease are widely accepted.⁴⁵ (adults)

Surgical intervention:

- Bariatric surgery should be considered in patients who are unsuccessful in other weight loss measures.

Referral Criteria

Diabetes educator: most children and families should be referred to a diabetes educator for initial and ongoing management.

Endocrinologist: Patients using insulin should have a consultation with an endocrinologist in regards to their care. Primary care providers can certainly provide overlap management of T1D.

- **Diabetic ketoacidosis** - a medical emergency, can cause coma and death. Hospitalization, usually in an intensive care unit, is necessary.
- **Nonketotic hyperglycemic-hyperosmolar coma** is treated much like diabetic ketoacidosis. The levels of sugar in the blood must be restored to normal levels gradually to avoid sudden shifts of fluid into the brain.
- **Women of childbearing age** – pre-pregnancy counseling and planning is important. Prior to pregnancy, glycemic control should be optimized, and both ACE inhibitor and statin medications should be discontinued.

Resources for Clinicians

American Diabetes Association. Standards of Medical Care in Diabetes. Summary of Revisions: Diabetes Care. 2019;42(Suppl 1):S4-S6.

Chamberlain JJ, Kalyani RR, Leal S, et al. Treatment of Type 1 Diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes. *Ann Intern Med.* 2017; 167(7):493-498.

Resources for Patients

Juvenile Diabetes Research Foundation. <http://jdrf.org/t1d-resources/>

National Center for Complementary and Alternative Medicine (part of the National Institute of Health) - <http://nccam.nih.gov/> - Search for Type 1 Diabetes

Clinical Pathway Feedback

CHP desires to keep our clinical pathways customarily updated. If you wish to provide additional input, please use the e-mail address listed below and identify which clinical pathway you are referencing. Thank you for taking the time to give us your comments.

Clinical Services Department: cs@chpgroup.com

Disclaimer Notice

The CHP Group (CHP) Clinical Pathways are a resource to assist clinicians, and are not intended to be nor should they be construed/used as medical advice. The pathways contain information that may be helpful for clinicians and their patients to make informed clinical decisions but they cannot account for all clinical circumstances. Each patient presents with specific clinical circumstances and values requiring individualized care, which may warrant adaptation from the pathway. Treatment decisions are made collaboratively by patients and their practitioner after an assessment of the clinical condition, consideration of options for treatment, any material risk, and an opportunity for the patient to ask any questions.

CHP makes no representation and accepts no liability with respect to the content of any external information cited or relied upon in the pathways. The presence of a particular procedure or treatment modality in a clinical pathway does not constitute a representation or warranty that this service is covered by a patient's benefit plan. The patient's benefit plan determines coverage.

¹ Bluestone JA, Buckner JH, Herold KC. Immunotherapy: Building a bridge to a cure for type 1 diabetes. *Science* (2021) 373(6554):510–6. doi: 10.1126/science.abh1654.

² Vehik K, Hamman RF, Lezotte D, et al. Increasing incidence of type 1 diabetes in 0- to 17-year-old Colorado youth. *Diabetes Care* 2007; 30:503.

³ Prevalence and incidence of type 1 diabetes in the world: a systematic review and meta-analysis. Majid Mobasseri,¹ Masoud Shirmohammadi,² Tarlan Amiri,³ Nafiseh Vahed,^{4, 5} Hossein Hosseini Fard,⁵ and Morteza

- Ghojatzadeh ^{5,*} *Health Promot Perspect*. 2020; 10(2): 98–115. Published online 2020 Mar 30. doi: 10.34172/hpp.2020.18 PMID: 32296622
- ⁴ Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al.. Idf diabetes atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. *Diabetes Res Clin Pract* (2022) 183:109119. doi: 10.1016/j.diabres.2021.109119.
- ⁵ Rhee TG, Westberg SM, Harris IM. Complementary and Alternative Medicine in U.S. Adults with Diabetes: Reasons for Use and Perceived Benefits. *J Diabetes*. 2017.
- ⁶ CDC National Diabetes Database Report 2020
- ⁷ Massimo Pietropaolo. Pathogenesis of type 1 diabetes mellitus. Up To Date. Sep 18, 2013.
- ⁸ Type 1 Diabetes Risk Factors Genes, ethnicity, and geography may all play a role Written by [Daphne E. Smith-Marsh PharmD, CDE](#) | Reviewed by [W. Patrick Zeller M](#). EndocrineWeb
- ⁹ Animal milk in the diet as a risk for T1D development and islet cell antibodies. A.M. Lampousi. Karolinska Institutet, Stockholm, systematic review and meta-analysis
- ¹⁰ [Guideline] Diagnosis and classification of diabetes mellitus. *Diabetes Care*. Jan 2010;33 Suppl 1:S62-9.
- ¹¹ American Association of Clinical Endocrinologists Statement on the Use of A1C for the Diagnosis of Diabetes. Available at <https://www.aace.com/files/AACEpositionA1cfeb2010.pdf>. Accessed October 13th, 2017.
- ¹² American Diabetes Association. Position Statement. Standards of medical care in diabetes – 2015. Abridged for primary care providers. *Clin Diabetes*. 2015;33(2):97-111.
- ¹³ American Diabetes Association. Standards of medical care in diabetes--2012. *Diabetes Care* 2012; 35 Suppl 1:S11.
- ¹⁴ James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA*. 2014;311:507–520.
- ¹⁵ Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. *J Hypertens*. 2014;32:3–15.
- ¹⁶ Dasgupta K, Quinn RR, Zarnke KB, et al. The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. *Can J Cardiol*. 2014;30:485–501.
- ¹⁷ American Diabetes Association. Standards of medical care in diabetes—2014. *Diabetes Care*. 2014;37(suppl 1):S14–S80.
- ¹⁸ National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. *Am J Kidney Dis* 2012;60:850–886
- ¹⁹ Thomas D, Elliott EJ. Low glycaemic index, or low glycaemic load, diets for diabetes mellitus. *Cochrane Database of Systematic Reviews* 2009, Issue 1.
- ²⁰ Wallin A, Di Giuseppe D, Orsini N, et al. Fish consumption, dietary long-chain n-3 fatty acids, and risk of type 2 diabetes: systematic review and meta-analysis of prospective studies. *Diabetes Care*. 2012;35(4):918-929.
- ²¹ Lu X, Zhao C, Exercise and Type 1 Diabetes. *Adv Exp Med Biol* . 2020;1228:107-121. doi: 10.1007/978-981-15-1792-1_7.
- ²² Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 2002; 346:393.
- ²³ Yudkin JS. How can we best prolong life? Benefits of coronary risk factor reduction in non-diabetic and diabetic subjects. *BMJ* 1993; 306:1313.
- ²⁴ Wyatt L, Ferrance R. The musculoskeletal effects of diabetes mellitus. *Journal Of The Canadian Chiropractic Association* [serial online]. March 2006;50(1):43-50.
- ²⁵ Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. *N Engl J Med* 2003; 348:383.
- ²⁶ Vuksan V, Sievenpiper JL, Wong J, et al. American ginseng (*Panax quinquefolius* L.) attenuates postprandial glycemia in a time-dependent but not dose-dependent manner in healthy individuals. *Am J Clin Nutr*. 2001 Apr;73(4):753-8.
- ²⁷ Vuksan V, Sievenpiper JL, Koo VY, et al. American ginseng (*Panax quinquefolius* L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus. *Arch Intern Med*. 2000 Apr 10;160(7):1009-13.

- ²⁸ Vuksan V, Stavro MP, Sievenpiper JL, et al. Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes. *Diabetes Care*. 2000 Sep;23(9):1221-6.
- ²⁹ Gholap S, Kar A. Hypoglycaemic effects of some plant extracts are possibly mediated through inhibition in corticosteroid concentration. *Pharmazie*. 2004 Nov;59(11):876-8.
- ³⁰ Agrawal P, Rai V, Singh RB. Randomized placebo-controlled, single blind trial of holy basil leaves in patients with noninsulin-dependent diabetes mellitus. *Int J Clin Pharmacol Ther*. 1996 Sep;34(9):406-9.
- ³¹ Gupta A, Gupta R, Lal B. Effect of *Trigonella foenum-graecum* (fenugreek) seeds on glycaemic control and insulin resistance in type 2 diabetes mellitus: a double blind placebo controlled study. *J Assoc Physicians India*. 2001 Nov;49:1057-61.
- ³² Gong J, Fang K, Dong H, et al. Effect of fenugreek on hyperglycaemia and hyperlipidemia in diabetes and prediabetes: a meta-analysis. *Journal of Ethnopharmacology*. 2016;194:260-268.
- ³³ Khan A, Safdar M, Ali Khan MM, et al. Cinnamon improves glucose and lipids of people with type 2 diabetes. *Diabetes Care*. 2003 Dec;26(12):3215-8.
- ³⁴ Costello RB, Dwyer JT, Saldanha L, Bailey RL, Merkel J, Wambogo E. Do Cinnamon Supplements Have a Role in Glycemic Control in Type 2 Diabetes? A Narrative Review. *J Acad Nutr Diet*. 2016; 116 (11):1794-1802.
- ³⁵ Shanmugasundaram ER, Rajeswari G, Baskaran K, et al. Use of *Gymnema sylvestre* leaf extract in the control of blood glucose in insulin-dependent diabetes mellitus. *J Ethnopharmacol*. 1990 Oct;30(3):281-94.
- ³⁶ Baskaran K, Kizar Ahamath B, Radha Shanmugasundaram K., et al. Antidiabetic effect of a leaf extract from *Gymnema sylvestre* in non-insulin-dependent diabetes mellitus patients. *J Ethnopharmacol*. 1990 Oct;30(3):295-300.
- ³⁷ Balasubramaniam K, Arasaratnam V, Nageswaran A, et al. Studies on the effect of *Gymnema sylvestre* on diabetics. *J Natl Sci Counc Sri Lanka* 1992;20(1):81-89.
- ³⁸ Meta-analysis of the effect of herbal supplement on glycemic control in type 2 diabetes. *Journal of Ethnopharmacology*. 2011;137(3):1328-1333. Suksomboon N, Poolsup N, Boonkaew S, et al.
- ³⁹ Urberg M, Zemel MB. Evidence for synergism between chromium and nicotinic acid in the control of glucose tolerance in elderly humans. *Metabolism*. 1987 Sep;36(9):896-9.
- ⁴⁰ Systematic review and meta-analysis of the efficacy and safety of chromium supplementation in diabetes Suksomboon N, Poolsup N, Yuwanakor
- ⁴¹ McCarty MF. High-dose biotin, an inducer of glucokinase expression, may synergize with chromium picolinate to enable a definitive nutritional therapy for type II diabetes. *Med Hypotheses*. 1999 May;52(5):401-6.
- ⁴² Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. Ziegler D, Gries FA. *Diabetes*. 1997 Sep;46 Suppl 2:S62-6. doi: 10.2337/diab.46.2.s62.PMID: 9285502 Review.
- Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. Ziegler D, Gries FA. *Diabetes*. 1997 Sep;46 Suppl 2:S62-6. doi: 10.2337/diab.46.2.s62.PMID: 9285502 Review.
- ⁴³ Effect of alpha-lipoic acid supplementation on lipid profile: A systematic review and meta-analysis of controlled clinical trials. Seyed Mohammad Mousavi 1, Sakineh Shab-Bidar 2, Hamed Kord-Varkaneh 2, Masoud Khorshidi 2, Kurosh Djafarian 3. *Nutrition*. 2019 Mar;59:121-130.doi: 10.1016/j.nut.2018.08.004. Epub 2018 Aug 23.
- ⁴⁴ Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. Ziegler D, Gries FA. *Diabetes*. 1997 Sep;46 Suppl 2:S62-6. doi: 10.2337/diab.46.2.s62. PMID: 9285502 Review.
- ⁴⁵ Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ* 2002; 324:71.